Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHA NASDAQ:COCP NASDAQ:JAGX NASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$0.36-5.8%$0.40$0.22▼$0.83$14.20M3.01155,634 shs619,818 shsCOCPCocrystal Pharma$1.58+9.7%$1.60$1.12▼$3.26$16.21M2.294.20 million shs82.95 million shsJAGXJaguar Animal Health$1.96-3.4%$2.12$1.57▼$35.25$4.26M0.58140,063 shs99,062 shsPRPHProPhase Labs$0.43-15.8%$0.37$0.22▼$2.83$18.01M-0.782.51 million shs5.59 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma0.00%-7.76%-9.57%+18.42%-26.53%COCPCocrystal Pharma0.00%+7.12%-5.95%+2.60%-3.07%JAGXJaguar Animal Health0.00%+10.73%-5.31%-43.84%-93.06%PRPHProPhase Labs0.00%+22.15%+30.38%+30.85%-83.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$0.36-5.8%$0.40$0.22▼$0.83$14.20M3.01155,634 shs619,818 shsCOCPCocrystal Pharma$1.58+9.7%$1.60$1.12▼$3.26$16.21M2.294.20 million shs82.95 million shsJAGXJaguar Animal Health$1.96-3.4%$2.12$1.57▼$35.25$4.26M0.58140,063 shs99,062 shsPRPHProPhase Labs$0.43-15.8%$0.37$0.22▼$2.83$18.01M-0.782.51 million shs5.59 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma0.00%-7.76%-9.57%+18.42%-26.53%COCPCocrystal Pharma0.00%+7.12%-5.95%+2.60%-3.07%JAGXJaguar Animal Health0.00%+10.73%-5.31%-43.84%-93.06%PRPHProPhase Labs0.00%+22.15%+30.38%+30.85%-83.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHAAthira Pharma 2.00Hold$0.5038.89% UpsideCOCPCocrystal Pharma 3.00Buy$6.00279.75% UpsideJAGXJaguar Animal Health 3.00Buy$60.002,961.22% UpsidePRPHProPhase Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest JAGX, ATHA, COCP, and PRPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $6.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/ACOCPCocrystal PharmaN/AN/AN/AN/A$0.94 per shareN/AJAGXJaguar Animal Health$11.69M0.36N/AN/A$12.29 per share0.16PRPHProPhase Labs$6.77M2.66N/AN/A$0.25 per share1.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHAAthira Pharma-$96.94M-$1.55N/AN/AN/AN/A-139.40%-106.84%11/6/2025 (Estimated)COCPCocrystal Pharma-$17.50M-$1.24N/AN/AN/AN/A-144.12%-102.85%11/12/2025 (Estimated)JAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-344.16%-660.18%-77.42%11/12/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-262.42%-76.48%11/12/2025 (Estimated)Latest JAGX, ATHA, COCP, and PRPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025COCPCocrystal Pharma-$0.30-$0.20+$0.10-$0.20N/AN/A8/14/2025Q2 2025JAGXJaguar Animal Health-$7.13-$10.26-$3.13-$10.26$3.27 million$2.98 million8/13/2025Q2 2025PRPHProPhase Labs-$0.15-$0.11+$0.04-$0.11$3.55 million$1.25 million8/7/2025Q2 2025ATHAAthira Pharma-$0.18-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHAAthira PharmaN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHAAthira PharmaN/A10.8110.81COCPCocrystal PharmaN/A3.693.69JAGXJaguar Animal Health2.440.950.59PRPHProPhase Labs0.200.960.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHAAthira Pharma57.12%COCPCocrystal Pharma6.72%JAGXJaguar Animal Health12.04%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipATHAAthira Pharma19.80%COCPCocrystal Pharma28.14%JAGXJaguar Animal Health4.55%PRPHProPhase Labs9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHAAthira Pharma4039.44 million31.63 millionOptionableCOCPCocrystal Pharma1010.26 million7.37 millionNot OptionableJAGXJaguar Animal Health502.17 million2.08 millionNo DataPRPHProPhase Labs13041.54 million37.55 millionOptionableJAGX, ATHA, COCP, and PRPH HeadlinesRecent News About These CompaniesProPhase Labs (NASDAQ:PRPH) Raised to Hold at Wall Street ZenSeptember 14 at 3:48 AM | americanbankingnews.comProPhase Labs (NASDAQ:PRPH) Stock Passes Above 200 Day Moving Average - Should You Sell?September 13 at 2:57 AM | americanbankingnews.comProPhase Labs stockholders approval all proposals at Special MeetingSeptember 12 at 3:38 PM | msn.comProPhase Labs, Inc.: ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In FavorSeptember 12 at 10:37 AM | finanznachrichten.deProPhase Labs Stockholders Approve Strategic Initiatives and Increase Authorized Shares at Special MeetingSeptember 12 at 8:31 AM | quiverquant.comQProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In FavorSeptember 12 at 8:00 AM | globenewswire.comProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025September 3, 2025 | markets.businessinsider.comProPhase Labs Inc. to Participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025September 3, 2025 | globenewswire.comProPhase Labs, Inc. (PRPH) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | seekingalpha.comProPhase Labs files definitive proxy statement for special meetingAugust 20, 2025 | msn.comProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of ShareholdersAugust 19, 2025 | globenewswire.comProPhase Labs Inc (PRPH) Q2 2025 Earnings Call Highlights: Strategic Moves and Future ProspectsAugust 15, 2025 | finance.yahoo.comProPhase Labs Reports Turnaround and Strategic GrowthAugust 14, 2025 | msn.comProPhase Labs Posts Narrower Q2 LossAugust 13, 2025 | aol.comAProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025August 13, 2025 | globenewswire.comProPhase Labs stock soars after securing patent for esophageal disease testAugust 12, 2025 | investing.comEarnings Preview For ProPhase LabsAugust 12, 2025 | benzinga.comProPhase Labs Shares Surge 38% Following Patent Approval for Esophageal Disease TestAugust 12, 2025 | msn.comWhy Is ProPhase Labs Stock (PRPH) Up 25% Today?August 12, 2025 | msn.comProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk AssessmentAugust 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNHBy Leo Miller | August 20, 2025With Rate Cuts Ahead, Buffett-Backed Builders Look Like a BuyBy Jordan Chussler | September 4, 2025Constellation Lowers Outlook: Time to Panic on Buffett's Big Bet?By Leo Miller | September 12, 2025JAGX, ATHA, COCP, and PRPH Company DescriptionsAthira Pharma NASDAQ:ATHA$0.36 -0.02 (-5.78%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.36 -0.01 (-1.39%) As of 09/12/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Cocrystal Pharma NASDAQ:COCP$1.58 +0.14 (+9.72%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.47 -0.11 (-6.96%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Jaguar Animal Health NASDAQ:JAGX$1.96 -0.07 (-3.45%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.00 +0.04 (+2.30%) As of 09/12/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.ProPhase Labs NASDAQ:PRPH$0.43 -0.08 (-15.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.44 +0.01 (+1.73%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
